Stock Events

Stock Events

MaxCyte 

€0.75
0
+€0.02+2.76% Thursday 06:01

Statistics

Day High
0.75
Day Low
0.75
52W High
2.38
52W Low
0.59
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-0.08
-0.07
-0.07
-0.06
Expected EPS
-0.06474836
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYE0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap195.7B
Thermo Fisher Scientific offers a range of cell engineering and life sciences solutions, competing in the cell therapy tools space with MaxCyte.
Danaher
DHR
Mkt Cap137.82B
Danaher, through its subsidiaries, provides bioprocessing technologies, including cell therapy manufacturing, competing with MaxCyte's cell engineering platforms.
Bio-Rad Laboratories
BIO
Mkt Cap8.07B
Bio-Rad Laboratories provides products and services for life science research and clinical diagnostics, including cell biology, competing with MaxCyte's offerings.
Pacific Biosciences of California
PACB
Mkt Cap510.38M
Pacific Biosciences offers genomic analysis solutions, and its advancements in gene editing and sequencing technologies present competition to MaxCyte's cell engineering technologies.
Illumina
ILMN
Mkt Cap20.57B
Illumina provides sequencing and array-based solutions for genetic analysis, indirectly competing with MaxCyte by advancing gene editing and cell therapy research.
Intellia Therapeutics
NTLA
Mkt Cap1.77B
Intellia Therapeutics is a leading genome editing company that competes with MaxCyte in the development of therapies using CRISPR/Cas9 technology.
Editas Medicine
EDIT
Mkt Cap341.57M
Editas Medicine operates in the genome editing field, directly competing with MaxCyte in the development of CRISPR-based therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.57B
CRISPR Therapeutics is focused on the development of gene-based medicines, including CRISPR/Cas9 technology, competing with MaxCyte in gene editing applications.
Sangamo Therapeutics
SGMO
Mkt Cap108.54M
Sangamo Therapeutics focuses on genomic medicine, using gene editing to develop cell and gene therapies that compete with MaxCyte's technology.

About

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Show more...
CEO
Mr. Maher Masoud
Employees
91
Country
United States
ISIN
US57777K1060

Listings

STU
DE
MYE0.STU
MU
DE
MYE0.MU
F
DE
MYE0.F
BOATS
BOATS
MXCT.BOATS

0 Comments

Share your thoughts

FAQ

What is MaxCyte stock price today?▼
The current price of MYE0.MU is €0.75 EUR — it has increased by +2.76% in the past 24 hours. Watch MaxCyte stock price performance more closely on the chart.
What is MaxCyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MaxCyte stocks are traded under the ticker MYE0.MU.
Is MaxCyte stock price growing?▼
MYE0.MU stock has risen by +4.93% compared to the previous week, the month change is a +12.88% rise, over the last year MaxCyte has showed a -68.16% decrease.
When is the next MaxCyte earnings date?▼
MaxCyte is going to release the next earnings report on May 13, 2026.
What were MaxCyte earnings last quarter?▼
MYE0.MU earnings for the last quarter are -0.08 EUR per share, whereas the estimation was -0.07 EUR resulting in a -17.96% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does MaxCyte have?▼
As of April 24, 2026, the company has 91 employees.
In which sector is MaxCyte located?▼
MaxCyte operates in the Health & Wellness sector.
When did MaxCyte complete a stock split?▼
MaxCyte has not had any recent stock splits.
Where is MaxCyte headquartered?▼
MaxCyte is headquartered in Rockville, United States.